CANTA Cantargia AB (publ)

STO · SE · Healthcare · Biotechnology · cantargia.com

1.480SEK+5.04%Mkt Cap: 35.19M $P/E: 2.18Today

Cantargia AB (publ), a biotechnology company, develops pharmaceuticals for treatment of cancer, inflammatory, and autoimmune diseases. The company is developing CAN04 (nadunolimab), an monoclonal antibody that can bind I…

Industry Peers

Biotechnology

Screen all

VRTX

Vertex Pharmaceuticals Incorporated - Common Stock

$127.85BUSDP/E 29.4

MRNA

Moderna, Inc. - Common Stock

$75.86BUSD

REGN

Regeneron Pharmaceuticals, Inc. - Common Stock

$75.69BUSDP/E 18.2

ARGX

argenx SE - American Depositary Shares

Revolution Medicines, Inc. - Common Stock

BeOne Medicines Ltd. - American Depositary Shares

$40.51BUSDP/E 63.9

RPRX

Royalty Pharma plc - Class A Ordinary Shares

$33.03BUSDP/E 30.7

ALNY

Alnylam Pharmaceuticals, Inc. - Common Stock

$29.40BUSDP/E 38.3

ROIV

Roivant Sciences Ltd. - Common Shares

$25.80BUSD

BNTX

BioNTech SE - American Depositary Shares

$24.34BUSD

INSM

Insmed Incorporated - Common Stock

$24.27BUSD

INCY

Incyte Corporation - Common Stock

Genmab A/S - American Depositary Shares

$21.69BUSDP/E 27.4

JAZZ

Jazz Pharmaceuticals plc - Ordinary Shares

$15.30BUSDP/E 16.1

ASND

Ascendis Pharma A/S - Ordinary Share

$14.99BUSDP/E 17.8

EXEL

Exelixis, Inc. - Common Stock

$14.47BUSDP/E 18.4

SMMT

Summit Therapeutics Inc. - Common Stock

$13.37BUSD

Key Statistics

Company

Market Cap35.19M USD

Enterprise Value12.28M USD

Revenue (TTM)30.35M USD

Gross Profit30.35M USD

Net Income (TTM)14.06M USD

Revenue/Share1.28 SEK

Last Price1.480 SEK

Fiscal Year EndDec 2025

MR QuarterJun 2026

Employees22

CountrySE

SectorHealthcare

IndustryBiotechnology

ISIN—

Valuation

P/E (Trailing)2.18

P/E (Forward)-1.50

PEG—

EV/EBITDA0.76

EV/Revenue0.40

P/S1.10

P/B1.33

EPS (TTM)0.68

EPS (Forward)-0.94

52W Range

1.3912% of range6.590

52W High6.590 SEK

52W Low1.391 SEK

Profitability

Gross Margin100.00%

Oper. Margin-37510.53%

EBITDA Margin53.13%

Profit Margin46.41%

ROE55.28%

ROA49.54%

Growth

Revenue Growth—

Earnings Growth—

Cash Flow & Leverage

Operating CF14.36M USD

CapEx (TTM)45.15K USD

FCF Margin10.00%

FCF Yield8.63%

Net Debt-21.23M USD

Net Debt/EBITDA-1.32

Balance Sheet

Debt/Equity—

Current Ratio7.03

Quick Ratio6.93

Book Value/Sh1.06 SEK

Cash/Share0.89 SEK

Dividends

Fwd Div Rate—

Trail. Div Rate0.00 SEK

Div. Yield0.00%

5Y Avg Yield—

Payout Ratio0.00%

Ex-Div Date—

Pay Date—

Analyst Consensus

Rating1.0 (Strong Buy)

Strong BuyBuyHoldSellStr. Sell

Target (Mean)8.250 SEK

Upside (mean)+457.4%

Target Range4.500 SEK – 12.00 SEK

4.500+457.4% to mean12.00

# Analysts2

Ownership

Shares Out.248.61M

Float237.72M

Insiders4.49%

Institutions26.80%

Technical

SMA 501.721 (-14.0%)

SMA 2003.215 (-54.0%)

Beta1.59

S&P 52W Chg14.58%

Avg Vol (30d)1.57M

Avg Vol (10d)2.46M

Technical Indicators

RSI (14)31.7

MACD-0.0927

MACD Signal-0.0908

MACD Hist.-0.0019

BB Upper1.731 SEK

BB Middle1.547 SEK

BB Lower1.364 SEK

BB Width23.75%

ATR (14)0.0988 SEK

Vol Ratio (20d)1.78x